Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Mirum Pharmaceuticals (NASDAQ:MIRM) had its target price increased by investment analysts at Citizens Jmp from $144.00 to $167.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp‘s price target points to a potential upside of 91.89% from the stock’s current price.

Several other brokerages have also recently weighed in on MIRM. TD Cowen lifted their price target on Mirum Pharmaceuticals from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Wednesday, October 21st. UBS Group set a $137.00 price target on Mirum Pharmaceuticals in a report on Thursday, August 27th. Wall Street Zen lowered Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, September 6th. HC Wainwright raised their price objective on shares of Mirum Pharmaceuticals from $200.00 to $202.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $189.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $153.56.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $87.03 on Wednesday. The stock has a 50-day simple moving average of $89.53 and a two-hundred day simple moving average of $98.42. The firm has a market capitalization of $5.65 billion, a P/E ratio of -5.98 and a beta of 0.75. Mirum Pharmaceuticals has a fifty-two week low of $63.23 and a fifty-two week high of $130.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. The company had revenue of $185.72 million during the quarter, compared to analyst estimates of $178.07 million. During the same period last year, the firm earned $0.05 EPS. The business’s quarterly revenue was up 39.6% compared to the same quarter last year. On average, equities analysts forecast that Mirum Pharmaceuticals will post -1.32 earnings per share for the current year.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 6,001 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total value of $599,499.90. Following the sale, the chief financial officer directly owned 36,355 shares of the company’s stock, valued at approximately $3,631,864.50. This trade represents a 14.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $98.68, for a total value of $2,960,400.00. Following the completion of the sale, the chief executive officer owned 194,440 shares of the company’s stock, valued at $19,187,339.20. This trade represents a 13.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 96,659 shares of company stock worth $9,604,100. 8.32% of the stock is owned by corporate insiders.

Institutional Trading of Mirum Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Commonwealth Equity Services LLC boosted its position in Mirum Pharmaceuticals by 10.8% during the third quarter. Commonwealth Equity Services LLC now owns 2,471 shares of the company’s stock worth $211,000 after acquiring an additional 241 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in Mirum Pharmaceuticals in the 3rd quarter worth approximately $284,000. Profund Advisors LLC lifted its stake in Mirum Pharmaceuticals by 24.1% in the 3rd quarter. Profund Advisors LLC now owns 18,939 shares of the company’s stock worth $1,619,000 after purchasing an additional 3,676 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Mirum Pharmaceuticals during the 3rd quarter worth approximately $248,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Mirum Pharmaceuticals by 22.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,848 shares of the company’s stock worth $1,037,000 after purchasing an additional 2,143 shares during the last quarter.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Revenue was $185.72 million, above estimates of about $178 million and up 39.6% year over year. Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Mirum said it would present new data across its rare liver disease portfolio at AASLD’s The Liver Meeting. The provided report does not detail the findings, so their potential impact is unclear. Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio
• Negative Sentiment: Mirum posted a quarterly loss of $0.87 per share, wider than analyst estimates of roughly $0.49–$0.53 per share and a reversal from earnings of $0.05 a year earlier. Mirum Pharmaceuticals Reports Q3 Loss, Tops Revenue Estimates

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the liver and bile acid pathways. The company’s medicines are designed to address conditions with limited treatment options and to improve outcomes for children and adults living with serious chronic diseases.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor used to treat cholestatic pruritus, or severe itching caused by impaired bile flow, in patients with Alagille syndrome and progressive familial intrahepatic cholestasis.